AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05658640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous
Study NCT05658640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intravenous
Study NCT05658640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal chemotherapy
Description: IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
Study NCT05379023 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TeleNP evaluation
Description: The intervention is the assessment modality. The intervention condition is TeleNP evaluation.
Study NCT05716607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OD dual-release Hydrocortisone
Description: Treatment with once-daily dual-release hydrocortisone
Study NCT05716607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TID Hydrocortisone
Description: Treatment with thrice-daily conventional immediate-release hydrocortisone
Study NCT06358508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sapphire 3 Coronary Dilatation Catheter
Description: To pre-dilate Chronic Total Occlusion (CTO) lesions in coronary arteries during the subject's index procedure with Sapphire 3 0.85mm, 1.0mm, and 1.25mm diameter Coronary Dilatation Catheters.
Study NCT05377216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block
Description: Left sided percutaneous stellate ganglion block
Study NCT04943068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bremelanotide
Description: Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector.
Study NCT04943068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will self-administer a Placebo subcutaneously (SC) via auto-injector.
Study NCT06521736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AAC-BCI device
Description: Participants without speech and severe movement disorders will be trained on the augmentative and alternative communication, brain-computer interface (AAC-BCI) system, using it for at least 10 hours per week in their homes for communication and other control functions. Participants will have daily support for using the AAC-BCI from trained caregivers along with intervention support from consultants and speech language pathologists.
Study NCT05162794 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Laparoscopy with excision
Description: Diagnostic laparoscopy will be performed to visually confirm endometriosis in the peritoneum. Then, the relevant tissue will be excised and a histology will be performed.
Study NCT05162794 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Laparoscopy without excision
Description: Diagnostic laparoscopy will be performed to visually confirm endometriosis in the peritoneum. However, no tissue will be excised and histology will not be performed.
Study NCT05162794 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medical treatment-as-usual
Description: Patients continue their hormonal and analgesic treatment-as-usual.
Study NCT05848843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given by vein (IV)
Study NCT05848843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Given by PO
Study NCT05926661 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NCC Support Toolkit
Description: Pre-discharge intervention-~* Set expectations for parents/caregivers to spend time bedside and attend rounds~* iPad for the families to use the Nemours App, download education materials and Facetime communication with medical personnel.~* Download Nemours App and teach them how to use it~* Education materials- to ease the use of medications, Oxygen and feeding~* Assistance with transportation, child care, parental work schedule for discharge teaching~Post Discharge intervention (Day 1-2):~• Video/Facetime call with the family to check equipment, home environment and answer questions about medications and formula~Post discharge intervention (Day 3-7):~• Phone call to the family to ensure transportation for their first follow-up appointment, answer questions about medications, Oxygen and feeding.
Study NCT05159882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-1442 and Dapagliflozin placebo
Description: THR-1442 tablets 20mg and Dapagliflozin tablets placebo
Study NCT05159882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg and THR1442 placebo
Description: Dapagliflozin tablets 10mg and THR-1442 tablets placebo
Study NCT05318560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% Injectable Solution
Description: for MPS
Study NCT05318560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozone
Description: for MPS
Study NCT05318560 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stretching exercise
Description: for MPS
Study NCT05650294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PL+ omega 3 fatty acids
Description: PL+ omega 3 fatty acids is a food supplement that combines krill oil and FO EE. The dose will be around 1250 mg EPA+DHA.
Study NCT05650294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PL+ omega 3 fatty acids
Description: PL+ omega 3 fatty acids is a food supplement that combines krill oil and FO EE. The dose will be around 1250 mg EPA+DHA.
Study NCT05650294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FO EE fatty acids
Description: A conventional fish oil food supplement containing EPA and DHA in the EE form. The dose will be 1250 mg EPA+DHA.
Study NCT05650294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: FO EE fatty acids
Description: A conventional fish oil food supplement containing EPA and DHA in the EE form. The dose will be 1250 mg EPA+DHA.
Study NCT05508516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shugan Dingtong decoction
Description: Patients will accept Shugan Dingtong decoction 150ml (twice, per day) for 12 weeks.
Study NCT05508516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine Hydrochloride
Description: Patients will accept duloxetine hydrochloride 20mg (twice, per day) for 12 weeks.
Study NCT06085560 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Message
Description: Usual care is provided by the FQHC for the screening option chosen.
Study NCT06085560 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Implementation Intention Intervention: Standard Message
Description: Implementation Intention Intervention module includes standard messaging in addition to the usual care provided by the FQHC for the screening option chosen.
Study NCT06085560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation Intention Intervention: Culturally-Targeted Message
Description: Implementation Intention Intervention module includes culturally-targeted framing of health information messages in addition to the usual care provided by the FQHC for the screening option chosen.
Study NCT05962840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: Patient will be treated with Telitacicept (Taiai the commercial name) 80 mg every week subcutaneously for 12 months
Study NCT05962840 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Telitacicept
Description: Patient will be treated with placebo of Telitacicept (Taiai the commercial name) 80 mg every week subcutaneously for 12 months
Study NCT05170542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab+S-1
Description: Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.
Study NCT05685680 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total mesorectal excision in rectal carcinoma
Description: total mesorectal excision laparoscopic versus open technique in management of rectal carcinoma
Study NCT05099887 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Procenta conformable barrier
Description: Wound care dressing biologic allograft
Study NCT05463211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trexo Plus Pediatric Exoskeleton
Description: Wearable pediatric robotic walker for the lower extremities
Study NCT05250752 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin 10 MG [Farxiga]
Description: Primary end-points are measure before (day 0), on treatment (day 1 and day 3) and after treatment (day 21)
Study NCT05013619 — intervention group
Intervention type: OTHER
Intervention: Circumstances of pain
Description: It will be questioned in which situations the pain occurred in the previous week (at rest from spasms, at rest from splints, on feeding, on moving, on dressing, at night, on exercise, on other treatments, on botulinum toxin application) and record as yes/no.
Study NCT05013619 — intervention group
Intervention type: OTHER
Intervention: Pain Questionnaire
Description: Participants will be asked to respond to the initial question Over the past month, have you experienced physical pain? (yes or no). Those responding yes will be asked Please indicate how severe your pain was over the past month, on average, with response options from 1 (very little pain) to 10 (extremely painful). They will be also asked to indicate How much the pain gets in the way of your daily activities over the past month from a low of 1 (does not get in the way at all) to 10 (unable to carry out activities because of the pain). Finally, they will be asked to indicate the body regions in which they experienced pain.
Study NCT05013619 — intervention group
Intervention type: OTHER
Intervention: Gross Motor Functional Classification System
Description: Severity of CP will be determined based on the Gross Motor Functional Classification System (GMFCS). GMFCS is a standardised measure that classifies gross motor functions in children with CP. Children in level I are very independent in motor functions while those in level V are the least independent
Study NCT05013619 — intervention group
Intervention type: OTHER
Intervention: The subtypes of Cerebral palsy
Description: The subtypes of CP will be classified, using the Swedish classification, into spastic (tetraplegia, diplegia and hemiplegia), ataxic, dyskinetic and mixed
Study NCT04748783 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Subject participants will rinse mouth one time for 60 seconds with 10 mL of sterile water.
Study NCT04748783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peroxyl
Description: Subject participants will rinse mouth one time for 60 seconds with 10 mL Peroxyl (1.5% w/v hydrogen peroxide) rinse
Study NCT04748783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Periogard
Description: Subject participants will rinse mouth one time for 60 seconds with 10 mL Periogard (0.12% Chlorhexidine Gluconate) rinse.
Study NCT04748783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Total Zero
Description: Subject participants will rinse mouth one time with Colgate Total Zero Fresh Breath (0.075% Cetylpyridinium Chloride) 20ml for 30 seconds
Study NCT04358471 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal AAVCAGsCD59
Description: AAVCAGsCD59 is administered as an intravitreal injection in the enrolled eye
Study NCT04358471 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Intravitreal Sham Injection
Description: Sham injection mimics a real injection in the enrolled eye
Study NCT06215729 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine rehabilitation treatment
Description: The routine rehabilitation treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.) Besides, the patients with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected, conducted by experienced rehabilitation therapists.
Study NCT06215729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: routine rehabilitation treatment
Description: The routine rehabilitation treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.) Besides, the patients with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected, conducted by experienced rehabilitation therapists.
Study NCT06215729 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional cognitive training
Description: including Memory training, attention training, and executive function training were conducted 2-5 times per week, lasting for 30-60 minutes each session, based on the patient's condition.
Study NCT06215729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted Cognitive Function Training
Description: Based on the patient's cognitive impairment assessment results, the training content includes Attention game training, Executive function program training, Logical reasoning training, Agility training, Memory training. The training is conducted seven days a week, once a day, for a duration of 30-45 minutes per session
Study NCT05087238 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBT
Description: Cognitive Behavior Therapy for PVC-specific anxiety education, in-vivo exposure, interoceptive exposure, behavioral activation, relapse prevention
Study NCT06277128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 3g
Description: Acute treatment phase: WS016, oral, 3g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 3g, once daily for 12 days.
Study NCT06277128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 6g
Description: Acute treatment phase: WS016, oral, 6g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 6g, once daily for 12 days.
Study NCT06277128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 12g
Description: Acute treatment phase: WS016, oral, 12g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 12g, once daily for 12 days.
Study NCT06277128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Acute treatment phase: Matching Placebo, oral, three times a day for 48 hours; Maintenance treatment phase: Matching Placebo, oral, once daily for 12 days.
Study NCT05145556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videolarygoscopy
Description: In a randomised order we evaluate the first pass success rate of the tracheal tube into the trachea.
Study NCT05145556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional laryngoscopy
Description: In a randomized order we evaluate the first pass success rate of the tracheal tube into the trachea.
Study NCT05635266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Specimen sample
Description: The study may require a tissue collection and/or a participant survey for participation. Most tissue collected will come from a blood draw; up to 100mL for the health condition group, 60mL for the exceptive condition group, and up to 180mL for the control group (if determined safe for the participant). Participant surveys may involve participant reported outcomes (PROs) or custom participant surveys.
Study NCT05414162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Hematooncology patients under CAR T-cell therapy will receive 3 MRI examinations: at baseline, within 2 weeks of start of CAR T-cell therapy, and at 6 months follow-up.
Study NCT05496192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab/rHuPH20
Description: Specified dose on specified days
Study NCT05496192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT05961644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine Subcutaneous Injection
Description: Cladribine subcutaneous injection, 10 mg daily, for 2-3 consecutive days (depending on individual dose)
Study NCT05961644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Chloride Injection Sodium
Description: 0.9% sodium chloride injected subcutaneously, 10 ml daily, for 2-3 consecutive days
Study NCT05899010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal progesterone 600mg daily
Description: If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH \<7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone \<10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.
Study NCT05899010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone 800mg daily
Description: If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH \<7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone \<10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.
Study NCT03937830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: 1,150 mg flat dose every 21 days, starting on day 1 of cycle 1
Study NCT03937830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin-Eluting Beads
Description: used for TACE (only in patients with HCC BCLC stage B)
Study NCT03937830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE with Doxorubicin-Eluting Beads (only in patients with HCC BCLC stage B) on Cycle 2. More TACE can be done if clinically necessary.
Study NCT03937830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 7.5 mg/kg dose every 21 days, starting on day 1 of cycle 2
Study NCT03937830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 300, 150 or 75 mg once on day 1 of cycle 1
Study NCT06282562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Description: Individualized High-Intensity Interval Training (HIIT) program with two exercise sessions per week for 12 weeks. The exercise sessions will be conducted on a stationary bike, with intensity tailored to each participant's maximum exercise capacity.
Study NCT04668144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cangrelor
Description: Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The total infusion will last 2 hours.
Study NCT04668144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The total infusion will last 2 hours.
Study NCT04668144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Prasugrel will be used in line with FDA recommendations using a 60mg LD followed by a 10mg daily maintenance dose started 24 hours after LD administration
Study NCT04668144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Prasugrel will be used in line with FDA recommendations using a 60mg LD followed by a 10mg daily maintenance dose started 24 hours after LD administration
Study NCT06117683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ADULT Sotair Device
Description: Sotair® device employs a flow limiting and pressure control valve mechanism.
Study NCT06108141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resident Education And Counseling on Household Firearm Safety
Description: An intervention that includes a self-directed online curriculum and virtual reality simulations, designed to teach firearm screening and counseling among clinicians.
Study NCT06108141 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified American Academy of Pediatrics Safer
Description: An intervention that includes a self-directed online curriculum.
Study NCT06200155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Given by PO
Study NCT06200155 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Niacin
Description: Given by PO